NovaBay Pharmaceuticals to Hold 2016 Fourth Quarter and Full Year Conference Call on March 23, 2017

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report 2016 fourth quarter and full year financial results after market close on Thursday, March 23. Management will hold an investment community conference call that day to discuss financial results and provide a Company update.

    
      
        
          DATE:
        
        
           
        
        
           
        
        
          Thursday, March 23
        
      
      
        
          TIME:
        
        
        
        
        
        
          4:30 p.m. ET / 1:30 p.m. PT
        
      
      
        
          DIAL IN:
        
        
        
        
        
        
          800-608-8202 from within the U.S.
        
      
      
        
        
        
        
        
        
        
          702-495-1913 from outside the U.S.
        
      
      
        
        
        
        
        
        
        
          Enter conference identification number 68570527
        
      
      
        
        
        
        
        
        
        
           
        
      
    
    

The live call also will be available at http://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 11:59 p.m. Pacific time April 23, 2017, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 68570527. The call will also be archived at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals is a biopharmaceutical company focusing on the commercialization of prescription Avenova® lid and lash hygiene for the eye care market. Avenova is formulated with Neutrox®, which is cleared by the U.S. Food and Drug Administration (FDA) as a 510(k) medical device. Neutrox is NovaBay’s pure hypochlorous acid. Data from a multicenter clinical study show that Avenova reduced bacterial load, the underlying cause of blepharitis, on ocular skin surface by more than 90%. Laboratory tests show that hypochlorous acid has potent antimicrobial activity in solution yet is non-toxic to mammalian cells and also neutralizes bacterial toxins. Avenova is marketed to optometrists and ophthalmologists throughout the U.S. by NovaBay’s direct medical salesforce. It is accessible from more than 90% of retail pharmacies in the U.S. through agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen.

Stay informed on NovaBay's progress:

Download our Mobile InvestorApp from the Apple Store or Google PlayLike us on FacebookFollow us on TwitterConnect with NovaBay on LinkedInJoin us on Google+Visit NovaBay's Website

View source version on businesswire.com: http://www.businesswire.com/news/home/20170316005319/en/

NovaBay ContactsFor NovaBay Avenova purchasing information, please contact:1-800-890-0329www.Avenova.comorFrom the CompanyThomas J. PaulsonChief Financial Officer510-899-8809Contact TomorInvestor ContactLHAJody [e-mail]